WO2017216763A1 - Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens - Google Patents

Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens Download PDF

Info

Publication number
WO2017216763A1
WO2017216763A1 PCT/IB2017/053584 IB2017053584W WO2017216763A1 WO 2017216763 A1 WO2017216763 A1 WO 2017216763A1 IB 2017053584 W IB2017053584 W IB 2017053584W WO 2017216763 A1 WO2017216763 A1 WO 2017216763A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
octane
diazabicyclo
sulfooxy
carboxamide
Prior art date
Application number
PCT/IB2017/053584
Other languages
English (en)
Inventor
Vijaykumar Jagdishwar Patil
Ravikumar Tadiparthi
Piyush Ambalal PATEL
Prasad DIXIT
Loganathan Velupillai
Mohammad Usman Shaikh
Rajib BHUNIYA
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of WO2017216763A1 publication Critical patent/WO2017216763A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the invention relates to nitrogen containing compounds, their preparation and their use in preventing or treating infections.
  • Emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating bacterial infections.
  • One way forward to treat bacterial infections, and especially those caused by resistant bacteria, is to develop newer antibacterial agents that can overcome the bacterial resistant.
  • Coates et al. ⁇ Br. J. Pharmacol. 2007; 152(8), 1147- 1154.) have reviewed novel approaches to developing new antibiotics.
  • the development of new antibacterial agents is a challenging task. For example, Gwynn et al. ⁇ Annals of the New York Academy of Sciences, 2010, 1213: 5- 19) have reviewed the challenges in discovery of antibacterial agents.
  • Several antibacterial agents have been described in the prior art (for example, see PCT International Application Nos.
  • antibacterial agents for preventing and/or treating bacterial infections, including those caused by bacteria that are resistant to known antibacterial agents.
  • the inventors have now surprisingly discovered nitrogen containing compounds having antibacterial activity.
  • nitrogen containing compounds methods for preparation of these compounds, pharmaceutical compositions comprising these compounds, and methods for preventing or treating bacterial infection in a subject using these compounds.
  • Ri, R 2 , R3 are each independently selected from the group consisting of H, OR4, NR4R5, CN, halogen, Ci-C 6 alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl; wherein said Ci-C 6 alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl are optionally substituted, with one or more of the group comprising of OH, 0(d-C 6 alkyl), NH 2 , NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl)(Ci-C 6 alkyl), CN or halogen;
  • R4 and R5 are each independently selected from the group consisting of H, Ci-C alkyl, heterocycloalkyl, wherein said Ci-Ce alkyl is optionally substituted, with one or more substituents selected from NH 2 , (Ci-C6 alkyl)OH, heterocycloalkyl; n is 1, 2, 3 or 4;
  • M is hydrogen or a cation.
  • compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutically effective amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutical composition comprising a compound of Formula (I) or a stereoisomer, or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • a methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutical composition comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • methods for increasing antibacterial effectiveness of an antibacterial agent in a subject comprising co- administering said antibacterial agent or a pharmaceutically acceptable derivative thereof with a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • the specification discloses nitrogen containing compounds having antibacterial properties.
  • Q-C6 alkyl refers to branched or unbranched acyclic hydrocarbon radical with 1 to 6 carbon atoms.
  • Typical non-limiting examples of "Ci-Ce alkyl” include methyl, ethyl, n-propyl, iso-propyl, w-butyl, sec-butyl, z ' so-butyl, reri-butyl, w-pentyl, iso- pentyl, feri-pentyl, neopentyl, seopentyl, 3-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and the like.
  • Ci-C 6 alkyl may be unsubstituted, or substituted with one or more substituents.
  • substituents include halogen, alkoxy, CN, SH, COOH, COOCi-C 6 alkyl, CONH 2 , OH, NH 2 , NHCOCH 3 , cycloalkyl, heterocyclo alkyl, heteroaryl, aryl and the like.
  • cycloalkyl refers to three to seven member cyclic hydrocarbon radicals.
  • the cycloalkyl group optionally incorporates one or more double or triple bonds, or a combination of double or triple bonds, but which is not aromatic.
  • Typical, non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • the cycloalkyl may be unsubstituted, or substituted with one or more substituents.
  • substituents include Ci-C 6 alkyl, halogen, alkoxy, CN, SH, COOH, COOCi- C 6 alkyl, CONH 2 , OH, NH 2 , NHCOCH 3 , heterocycloalkyl, heteroaryl, aryl, S0 2 -alkyl, S0 2 -aryl, OS0 2 -alkyl, OS0 2 -aryl and the like.
  • aryl refers to a monocyclic or polycyclic aromatic hydrocarbon. Typical, non-limiting examples of aryl groups include phenyl, naphthyl, anthracenyl, flourenyl, phenanthrenyl, indenyl and the like. The aryl group may be unsubstituted, or substituted with one or more substituents.
  • substituents include C 1 -C6 alkyl, halogen, alkoxy, CN, COOH, CONH 2 , OH, NH 2 , NHCOCH3, heterocycloalkyl, heteroaryl, aryl, S0 2 -alkyl, S0 2 -aryl, OS0 2 -alkyl, OS0 2 -aryl and the like.
  • aryl includes six to fourteen membered monocyclic or polycyclic aromatic hydrocarbon.
  • heteroaryl refers to a monocyclic or polycyclic aromatic hydrocarbon group wherein one or more carbon atoms have been replaced with heteroatoms selected from nitrogen, oxygen, and sulfur. If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different.
  • heteroaryl groups include pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furanyl, pyrrolyl, thienyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazonyl, isoxazolyl, oxadiazolyl, oxatriazolyl, isothiazolyl, thiatriazolyl, thiazinyl, oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, tetrazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazolinyl,
  • the heteroaryl group may be unsubstituted, or substituted with one or more substituents.
  • substituents include Ci-C 6 alkyl, halogen, alkoxy, CN, COOH, CONH 2 , OH, SH, SCH 3 , NH 2 , NHCOCH 3 , heterocycloalkyl, heteroaryl, aryl, S0 2 -alkyl, S0 2 -aryl, OS0 2 -alkyl, OS0 2 -aryl and the like.
  • heteroaryl includes five to fourteen membered monocyclic or polycyclic aromatic hydrocarbon group containing at least one heteroatom selected from nitrogen, oxygen, and sulfur.
  • heterocycloalkyl refers to three to seven member cycloalkyl group containing one or more heteroatoms selected from nitrogen, oxygen or sulfur.
  • the heterocycloalkyl group optionally incorporates one or more double or triple bonds, or a combination of double bonds and triple bonds, but which is not aromatic.
  • heterocycloalkyl groups include aziridinyl, azetidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, imidazolidin-2-one-yl, piperidinyl, oxazinyl, thiazinyl, piperazinyl, piperazin-2,3-dione-yl, morpholinyl, thiomorpholinyl, azepanyl, and the like.
  • the heterocycloalkyl may be unsubstituted, or substituted with one or more substituents.
  • substituents include Ci-Ce alkyl, halogen, alkoxy, CN, COOH, CONH 2 , OH, NH 2 , NHCOCH3, heteroaryl, aryl, S0 2 -alkyl, S0 2 -aryl, OS0 2 -aryl and the like.
  • heterocycloalkyl includes three to seven membered cycloalkyl containing at least one heteroatom selected from nitrogen, oxygen, and sulfur.
  • halogen or halo as used herein refers to chlorine, bromine, fluorine or iodine.
  • Boc as used herein refers to fert-butyloxycarbonyl group
  • stereoisomers refers to compounds that have identical chemical constitution, but differ with regard to the arrangement of their atoms or groups in space.
  • the compounds of Formula (I) may contain asymmetric or chiral centers and, therefore, exist in different stereoisomeric forms. It is intended, unless specified otherwise, that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers (including cis and trans-forms), as well as mixtures thereof, are embraced within the scope of the invention.
  • a reference to a compound is intended to cover its stereoisomers and mixture of various stereoisomers.
  • substitution is optional and therefore includes both unsubstituted and substituted atoms and moieties.
  • a "substituted" atom or moiety indicates that any hydrogen on the designated atom or moiety can be replaced with a selection from the indicated substituent group, provided that the normal valency of the designated atom or moiety is not exceeded, and that the substitution results in a stable compound.
  • pharmaceutically acceptable derivative refers to and includes any pharmaceutically acceptable salt, pro-drug, metabolite, ester, ether, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, upon administration to a subject, is capable of providing (directly or indirectly) the parent compound.
  • antibacterial agent or a pharmaceutically acceptable derivative thereof includes all derivatives of the antibacterial agent (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, and adducts) which, upon administration to a subject, are capable of providing (directly or indirectly) the antibacterial agent.
  • pharmaceutically acceptable salt refers to one or more salts of a given compound which possesses the desired pharmacological activity of the free compound and which are neither biologically nor otherwise undesirable.
  • pharmaceutically acceptable salts refer to salts that are suitable for use in contact with the tissues of human and animals without undue toxicity, irrigation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. (/. Pharmaceutical Sciences, 66; 1-19, 1977), incorporated herein by reference in its entirety, describes various pharmaceutical acceptable salts in details.
  • the compounds according to the invention contain basic (e.g. nitrogen atoms) as well as acid moieties (e.g. compounds of Formula (I) wherein M is hydrogen).
  • acid moieties e.g. compounds of Formula (I) wherein M is hydrogen.
  • Such compounds can form acidic salts (formed with inorganic and/or organic acids), as well as basic salts (formed with inorganic and/or organic bases).
  • Such salts can be prepared using procedures described in the art.
  • the basic moiety can be converted to its salt by treating a compound with a suitable amount of acid.
  • suitable acids include hydrochloric acid, trifluoro acetic acid, methanesulfonic acid or the like.
  • the acid moiety may be converted into its salt by treating with a suitable base.
  • suitable bases include sodium carbonate, sodium bicarbonate, sodium ethylhexanoate, potassium carbonate, potassium bicarbonate, potassium ethyl hexanoate or the like.
  • each such functional group may be converted to salt independently.
  • one of the basic nitrogen can form salt with one acid while the other basic nitrogen can form salt with another acid.
  • infection or "bacterial infection” as used herein includes presence of bacteria, in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject.
  • infection in addition to referring to the presence of bacteria also refers to presence of other floras, which are not desirable.
  • infection includes infection caused by bacteria.
  • treat refers to administration of a medicament, including a pharmaceutical composition, or one or more pharmaceutically active ingredients, for prophylactic and/or therapeutic purposes.
  • prophylactic treatment refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at a risk of infection (preventing the bacterial infection).
  • therapeutic treatment refers to administering treatment to a subject already suffering from infection.
  • treat also refer to administering compositions, or one or more of pharmaceutically active ingredients discussed herein, with or without additional pharmaceutically active or inert ingredients, in order to: (i) reduce or eliminate either a bacterial infection, or one or more symptoms of a bacterial infection, or (ii) retard progression of a bacterial infection, or one or more symptoms of a bacterial infection, or (iii) reduce severity of a bacterial infection, or one or more symptoms of a bacterial infection, or (iv) suppress clinical manifestation of a bacterial infection, or (v) suppress manifestation of adverse symptoms of a bacterial infection.
  • a “therapeutically effective amount” or “pharmaceutically effective amount” or “effective amount” as used herein refer to an amount, which has a therapeutic effect or is the amount required to produce a therapeutic effect in a subject.
  • a “therapeutically effective amount” or “pharmaceutically effective amount” or “effective amount” of an antibacterial agent or a pharmaceutical composition is the amount of the antibacterial agent or the pharmaceutical composition required to produce a desired therapeutic effect as may be judged by clinical trial results, model animal infection studies, and/or in vitro studies (e.g. in agar or broth media).
  • Such effective amount depends on several factors, including but not limited to, the microorganism (e.g.
  • a prophylactically effective amount is that amount which would be effective in preventing the bacterial infection.
  • administration refers to and includes delivery of a composition, or one or more pharmaceutically active ingredients to a subject, including for example, by any appropriate method, which serves to deliver the composition or its active ingredients or other pharmaceutically active ingredients to the site of infection.
  • the method of administration may vary depending on various factors, such as for example, the components of the pharmaceutical composition or type/nature of the pharmaceutically active or inert ingredients, site of the potential or actual infection, the microorganism involved, severity of the infection, age and physical condition of the subject and a like.
  • Some non-limiting examples of ways to administer a composition or a pharmaceutically active ingredient to a subject according to this invention include oral, intravenous, topical, intrarespiratory, intraperitoneal, intramuscular, parenteral, sublingual, transdermal, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
  • a pharmaceutical composition comprising more than one ingredients (active or inert)
  • one of the ways of administering such composition is by admixing the ingredients (e.g. in the form of a suitable unit dosage form such as tablet, capsule, solution, powder or a like) and then administering the dosage form.
  • the ingredients may also be administered separately (simultaneously or one after the other) as long as these ingredients reach beneficial therapeutic levels such that the composition as a whole provides a synergistic and/or desired effect.
  • growth refers to a growth of one or more microorganisms and includes reproduction or population expansion of the microorganism (e.g. bacteria).
  • growth also includes maintenance of on-going metabolic processes of the microorganism, including the processes that keep the microorganism alive.
  • an antibacterial effectiveness refers to the ability of the composition or the antibacterial agent to prevent or treat bacterial infection in a subject.
  • antibacterial agent refers to any substance, compound, a combination of substances, or a combination of compounds capable of: (i) inhibiting, reducing or preventing growth of bacteria; (ii) inhibiting or reducing ability of a bacteria to produce infection in a subject; or (iii) inhibiting or reducing ability of bacteria to multiply or remain infective in the environment.
  • antibacterial agent also refers to compounds capable of decreasing infectivity or virulence of bacteria.
  • beta- lactamase or "beta-lactamase enzyme” as used herein refers to any enzyme or protein or any other substance that breaks down a beta-lactam ring.
  • beta-lactamase includes enzymes that are produced by bacteria and have the ability to hydrolyze the beta-lactam ring in a beta-lactam compound, either partially or completely.
  • beta-lactamase inhibitor refers to a compound capable of inhibiting activity of one or more beta-lactamase enzymes, either partially or completely.
  • pharmaceutically inert ingredient or “carrier” or “excipient” refers to and includes compounds or materials used to facilitate administration of a compound, for example, to increase the solubility of the compound.
  • solid carriers include starch, lactose, dicalcium phosphate, sucrose, and kaolin.
  • Typical, non-limiting examples of liquid carriers include sterile water, saline, buffers, non-ionic surfactants, and edible oils.
  • various adjuvants commonly used in the art may also be included. These and other such compounds are described in literature, e.g., in the Merck Index (Merck & Company, Rahway, N.J.).
  • subject refers to vertebrate or invertebrate, including a mammal.
  • subject includes human, animal, a bird, a fish, or an amphibian.
  • Typical, non-limiting examples of a “subject” include humans, cats, dogs, horses, sheep, bovine cows, pigs, lambs, rats, mice and guinea pigs.
  • cation refers to all organic and inorganic positively charged ions.
  • organic cation refers to all positively charged organic ions. Typical, non-limiting examples of organic cations include unsubstituted ammonium cations, alkyl substituted ammonium cations, cycloalkyl substituted ammonium cations, primary, secondary and tertiary amines, alkyl amines, cycloalkyl amines, aryl amines, NN'-dibenzylethylenediamine and the like.
  • inorganic cation refers to a positively charged metal ion. Typical, non-hmiting examples of inorganic cations include Group I and Group II metal cations such as, for example, lithium, sodium, potassium, rubidium, cesium, beryllium, magnesium, calcium and the like.
  • Ri, R 2 , R3 are each independently selected from the group consisting of H, OR4, NR4R5, CN, halogen, Ci-C 6 alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl; wherein said -C6 alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl are optionally substituted with one or more of the group comprising of OH, 0(d-C 6 alkyl), NH 2 , NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl)(Ci-C 6 alkyl), CN or halogen;
  • R4 and R5 are each independently selected from the group consisting of H, Ci-Ce alkyl, heterocycloalkyl, wherein said C1-C6 alkyl is optionally substituted with one or more substituents selected from N3 ⁇ 4, (Ci-C 6 alkyl)0H, heterocycloalkyl; n is 1, 2, 3 or 4;
  • M is hydrogen or a cation.
  • Typical, non-limiting examples of compounds according to the invention include:
  • the compounds of the invention can be prepared according to the general procedures given in Scheme 1.
  • a person of skills in the art would appreciate that the described method can be varied or optimized further to provide the desired and related compounds.
  • all variables are as defined above.
  • compound of Formula (II) is reacted with a suitable carboxyl activating agent in presence of a suitable solvent at a temperature of about 0-30°C for about 1-24 hours to obtain a compound of Formula (III).
  • compound of Formula (II) is reacted with thionyl chloride in presence of methanol at room temperature for about 16 hours to obtain a compound of Formula (III).
  • the so obtained compound of Formula (III) is treated with a suitable protecting agent to obtain a compound of Formula (IV).
  • the compound of Formula (IV) is subjected to reduction to obtain a compound of Formula (V).
  • suitable reducing agents include lithium aluminium hydride, lithium borohydride, sodium borohydride and like.
  • the compound of Formula (V) is treated with triphenyl phosphine and N-hydroxy phthalamide in presence of diisopropyl azodicarboxylate to obtain a compound of Formula (VI).
  • the compound of Formula (VI) is treated with hydrazine hydrate to obtain a compound of Formula (VII).
  • the so obtained compound of Formula (VII) is treated with sodium salt of (2S, 5R)-6- benzyloxy-7-oxo-l,6-diaza-bicyclo [3.2.1] octane- 2-carboxylic acid (VIII), (prepared as per the procedure disclosed in International Patent Application No.
  • suitable coupling agents include dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1), diisopropylcarbodiimide (DIC), 1- hydroxybenzotriazole (HOBt), N-hydroxysuccinimide (HOSu), 1 -Hydro xy-7-azabenzotriazolo (HO At), (l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3- oxidhexafluorophosphate) (HATU), PyBOP, PyBrop,
  • Suitable solvents include N,N-dimethylformamide, N,N-dimethylacetamide, 1,4-dioxane, chloroform, dichloromethane, tetrahydrofuran, acetonitrile, water and their appropriate combinations and the like.
  • the compound of Formula (IX) is debenzylated by carrying out hydrogeno lysis in presence of hydrogen, transition metal catalyst and a suitable solvent at a temperature ranging from about 10°C to about 60°C for about 1 hour to about 14 hour to provide a compound of Formula (X).
  • hydrogen source include hydrogen gas, ammonium formate, cyclohexene, lithium -liquid ammonia, ammonia - ieri-butanol, sodium - liquid ammonia - tert- butanol, triethyl silyl hydride and the like.
  • transition metal catalyst include 5% palladium on carbon, 10% palladium on carbon, 20% palladium hydroxide on carbon, Raney-Nickel and the like.
  • suitable solvent include methanol, ethanol, dichloromethane, N,N dimethylformamide, ethyl acetate, tetrahydrofuran or a mixture thereof.
  • the compound of Formula (X) is sulfonated by reacting with suitable sulfonating reagent in a suitable solvent such as pyridine, dichloromethane or NN-dimethylformamide, at a temperature ranging from about 0°C to about 80°C for about 1 hour to about 24 hour.
  • suitable solvent such as pyridine, dichloromethane or NN-dimethylformamide
  • Suitable sulfonating reagent include sulfur trioxide pyridine complex, sulfur trioxide trimethylamine complex, sulfur trioxide triethylamine complex, sulfur trioxide NN-dimethylaniline complex, sulfur trioxide 2-methylpyridine complex, sulfur trioxide dioxane complex, sulfur trioxide thioxane complex, sulfur trioxide dimethyl sulfide complex, sulfur trioxide dimethylsulfoxide complex, sulfur trioxide N,N-dimethylformamide complex and the like.
  • the obtained sulfonated compound was converted to corresponding tetrabutylammonium salt of Formula (XI).
  • the sulfonated compound is treated with tetrabutylammonium sulfate (TBAS) or tetrabutylammounium acetate (TBAA) to obtain tetrabutylammonium salt of sulfonic acid compound of Formula (XI).
  • TBAS tetrabutylammonium sulfate
  • TBAA tetrabutylammounium acetate
  • the compound according to the invention is then isolated as zwitterion, by removing the protecting groups of compound of Formula (XI).
  • the compound of Formula (XI) is reacted with suitable deprotecting agent such as trifluoro acetic acid in presence of a suitable solvent such as dichloromethane, chloroform or acetonitrile, at a temperature ranging from about - 15°C to about 40°C for about 0.5 hour to about 14 hour to obtain a compound of Formula (I), wherein M is H.
  • suitable solvent such as dichloromethane, chloroform or acetonitrile
  • compound of Formula (XI) was dissolved in suitable solvent such as 10% tetrahydrofuran: water mixture and was passed through the column packed with Dowex 50WX8 200 Na+ resin or passing through Indion 225 Na resin to provide sodium salt of compound of Formula (I).
  • compound of Formula (XI) was dissolved in suitable solvent such as acetone, tetrahydrofuran, ethanol, isopropanol or acetonitrile and thereby treating with sodium ethylhexanoate or potassium ethylhexanoate to provide sodium or potassium salt of compound of Formula (I).
  • compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, avibactam or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent selected from cefepime, cefpirome, ceftaroline, ceftazidime, ceftalozane or a pharmaceutically acceptable derivative thereof.
  • compositions comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lacatamse inhibitor or a pharmaceutically acceptable derivative thereof, and (c) at least one antibacterial agent, or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising: (a) a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof and (b) at least one beta-lactamase inhibitor or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising: (a) a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof and (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, avibactam, or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and (b) at least one antibacterial agent selected from selected from cefepime, cefpirome, ceftaroline, ceftazidime, ceftalozane or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a pharmaceutical composition comprising: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lactamase inhibitor or pharmaceutically acceptable derivative thereof and (c) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lactamase inhibitor or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, avibactam, or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one antibacterial agent or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one antibacterial agent selected from selected from cefepime, cefpirome, ceftaroline, ceftazidime, ceftalozane or pharmaceutically acceptable derivative thereof.
  • methods for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lactamase inhibitor or pharmaceutically acceptable derivative thereof, and (c) at least one antibacterial agent or pharmaceutically acceptable derivative thereof.
  • compositions and methods according to the invention use compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof in combination with at least one antibacterial agent or a pharmaceutically acceptable derivative thereof.
  • antibacterial agents include one or more of antibacterial compounds generally classified as aminoglycosides, ansamycins, carbacephems, cephalosporins, cephamycins, lincosamides, lipopeptides, macrolides, monobactams, nitrofurans, penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, oxazolidinone and the like.
  • aminoglycoside antibacterial agents include amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, arbekacin, streptomycin, apramycin and the like.
  • aminoglycoside antibacterial agents include amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, arbekacin, streptomycin, apramycin and the like.
  • ansamycin antibacterial agents include geldanamycin, herbimycin and the like.
  • carbacephem antibacterial agents include loracarbef and the like.
  • carbapenem antibacterial agents include ertapenem, doripenem, imipenem, meropenem and the like.
  • cephalosporin and cephamycin antibacterial agents include cefazolin, cefacetrile, cefadroxil, cefalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazedone, cefazaflur, cefradine, cefroxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cephamycin, cefoxitin, cefotetan, cefmetazole, carbacephem, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmen
  • lincosamide antibacterial agents include clindamycin, lincomycin and the like.
  • macrolide antibacterial agents include azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, solithromycin and the like.
  • monobactam antibacterial agents include aztreonam and the like.
  • nitrofuran antibacterial agents include furazolidone, nitrofurantoin and the like.
  • penicillin antibacterial agents include amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, temocillin, ticarcillin and the like.
  • polypeptide antibacterial agents include bacitracin, colistin, polymyxin B and the like.
  • quinolone antibacterial agents include ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, levonadifloxacin, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, temafloxacin and the like.
  • Typical, non-hmiting examples of sulfonamide antibacterial agents include mafenide, sulfonamidochrysoidine, sulfacetamide, sulfadiazine, sulfamethizole, sulfamethoxazole, sulfasalazine, sulfisoxazole, trimethoprim and the like.
  • Typical, non-limiting examples of tetracycline antibacterial agents include demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, tigecycline and the like.
  • Typical, non-limiting examples of oxazolidinone antibacterial agents include tedizolid, linezolid, ranbezolid, torezolid, radezolid and the like.
  • compositions according to the invention may include one or more pharmaceutically acceptable carriers or excipients or the like.
  • Typical, non-limiting examples of such carriers or excipient include mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, wetting agents, emulsifying agents, solubilizing agents, pH buffering agents, lubricants, stabilizing agents, binding agents etc.
  • compositions according to the present invention are administered orally or parenterally.
  • compositions according to this invention can exist in various forms.
  • the pharmaceutical composition is in the form of a powder or a solution.
  • the pharmaceutical compositions according to the invention are in the form of a powder that can be reconstituted by addition of a compatible reconstitution diluent prior to parenteral administration.
  • a compatible reconstitution diluent includes water.
  • the pharmaceutical compositions according to the invention are in the form of a frozen composition that can be diluted with a compatible diluent prior to parenteral administration.
  • the pharmaceutical compositions according to the invention are in the form ready to use for oral or parenteral administration.
  • the pharmaceutical composition and/or other pharmaceutically active ingredients disclosed herein may be administered by any appropriate method, which serves to deliver the composition or its constituents or the active ingredients to the desired site.
  • the method of administration can vary depending on various factors, such as for example, the components of the pharmaceutical composition and nature of the active ingredients, the site of the potential or actual infection, the microorganism (e.g. bacteria) involved, severity of infection, age and physical condition of the subject.
  • compositions to a subject according to this invention include oral, intravenous, topical, intrarespiratory, intraperitoneal, intramuscular, parenteral, sublingual, transdermal, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop or mouthwash.
  • compositions according to the invention can be formulated into various dosage forms wherein the active ingredients and/or excipients may be present either together (e.g. as an admixture) or as separate components.
  • the various ingredients in the composition are formulated as a mixture, such composition can be delivered by administering such a mixture to a subject using any suitable route of administration.
  • pharmaceutical compositions according to the invention may also be formulated into a dosage form wherein one or more ingredients (active or inactive ingredients) are present as separate components.
  • the composition or dosage form wherein the ingredients do not come as a mixture, but come as separate components, such composition/dosage form may be administered in several ways. In one possible way, the ingredients may be mixed in the desired proportions and the mixture is then administered as required. Alternatively, the components or the ingredients (active or inert) may be separately administered (simultaneously or one after the other) in appropriate proportion so as to achieve the same or equivalent therapeutic level or effect as would have been achieved by administration of the equivalent mixture.
  • compositions according to the invention are formulated into a dosage form such that the compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and the antibacterial agent or a pharmaceutically acceptable derivative thereof, are present in the composition as admixture or as separate components.
  • pharmaceutical compositions according to the invention are formulated into a dosage form such that the compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and the antibacterial agent or a pharmaceutically acceptable derivative thereof, are present in the composition as separate components.
  • the active ingredients disclosed herein may be administered to a subject in several ways depending on the requirements.
  • the active ingredients are admixed in appropriate amounts and then the admixture is administered to a subject.
  • the active ingredients are administered separately.
  • the invention further provides for combining separate pharmaceutical compositions in kit form.
  • the kit may comprise one or more separate pharmaceutical compositions, each comprising one or more active ingredients. Each of such separate compositions may be present in a separate container such as a bottle, vial, syringes, boxes, bags, and the like.
  • the kit comprises directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral) ore are administered at different dosage intervals.
  • the active ingredients are administered separately, they may be administered simultaneously or sequentially.
  • compositions or the active ingredients according to the present invention may be formulated into a variety of dosage forms.
  • dosage forms include solid, semi-solid, liquid and aerosol dosage forms; such as tablets, capsules, powders, solutions, suspensions, suppositories, aerosols, granules, emulsions, syrups, elixirs and a like.
  • compositions and methods disclosed herein are useful in preventing or treating bacterial infections.
  • compositions and methods disclosed herein are also effective in preventing or treating infections caused by bacteria that are considered be less or not susceptible to one or more of known antibacterial agents or their known compositions.
  • Some non-limiting examples of such bacteria known to have developed resistance to various antibacterial agents include Acinetobacter, E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacter, Klebsiella, Citrobacter and a like.
  • infections that may be prevented or treated using the compositions and/or methods of the invention include: skin and soft tissue infections, febrile neutropenia, urinary tract infection, intraabdominal infections, respiratory tract infections, pneumonia (nosocomial), bacteremia meningitis, surgical, infections etc.
  • the compounds, compositions and methods according to the invention are also effective in preventing or treating bacterial infections that are caused by bacteria producing one or more beta-lactamase enzymes.
  • methods of inhibiting beta-lactamase enzymes comprisin said methods comprise administering a pharmaceutically effective amount of a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods of inhibiting beta- lactamase enzymes comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • the compounds of Formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof according to invention are also useful in increasing antibacterial effectiveness of antibacterial agent in a subject.
  • the antibacterial effectiveness of one or more antibacterial agents may increased, for example, by co-administering said antibacterial agent or a pharmaceutically acceptable derivative thereof with a pharmaceutically effective amount of a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof according to the invention.
  • a method for increasing antibacterial effectiveness of the antibacterial agent in a subject comprising co- administering said antibacterial agent or a pharmaceutically acceptable derivative thereof with a of a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • Step 1 Synthesis of ethyl 3-aminobenzoate hydrochloride: Thionyl chloride (32.53 g, 0.273 mol) was added drop-wise to a solution of 4-aminobenzoic acid (15 g, 0.109 mol) in ethanol (150 ml) under stirring at 0°C. The reaction mixture was allowed to warm to room temperature and then further heated to 80°C for 16 hours. The resulting mixture was concentrated under reduced pressure and to the obtained residue diethyl ether was added (150 ml) and stirred for 15 minutes. The separated solid was filtered and washed with fresh diethyl ether (30 ml). The residue was dried, under reduced pressure to obtain 18 g of the titled product as white solid in 82% yield.
  • Step 2 Synthesis of ethyl 3-[(tert-butoxycarbonyl)amino]benzoate: BOC anhydride (58.44 g, 0.267 mol) was added to a solution of ethyl 3-aminobenzoate hydrochloride (18 g, 0.089 mol), in dichloromethane (180 ml) containing triethylamine (22.53 g, 0.223 mol), under stirring, at 0°C. The resulting mixture was allowed to warm to room temperature and stirred for 16 hour. The resulting mixture was washed with plain water (2 x 50 ml), dried over sodium sulfate then concentrated under reduced pressure to obtain oil.
  • BOC anhydride 58.44 g, 0.267 mol
  • Step 3 Synthesis of tert-butyl [3-(hydroxymethyl)phenyl]carbamate: To solution of ethyl 3- [(iert-butoxycarbonyl)amino]benzoate (14 g, 0.052 mol) in tetrahydrofuran (70 ml) was added slowly to a solution of lithium aluminium hydride (2 g, 0.052 mol) in tetrahydrofuran (70 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction mixture was quenched with a saturated aqueous solution of sodium sulfate. The resulting mixture was filtered through celite bed and the residue washed with fresh tetrahydrofuran (30 ml). The solvent from the combined filtrate was evaporated under reduced pressure to obtain 9 g of the titled product as white solid in 78% yield.
  • Step 4 Synthesis of tert-butyl-(3- ⁇ [(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)oxy]methyl ⁇ phenyl)carbamate: To a solution of tert-butyl [3-(hydroxymethyl)phenyl]carbamate (9 g, 0.040 mol) in tetrahydrofuran (90 ml), was added triphenylphosphine (8.96 g, 0.044 mol), N-hydroxy phthalimide (6.65 g, 0.040 mol) and diisopropylazodicarboxylate (12.78 g, 0.048 mol) under stirring at room temperature.
  • Step 5 Synthesis of teri-butyl ⁇ 3-[(aminooxy)methyl]phenyl ⁇ carbamate: To a solution of tert- butyl [3-(hydroxymethyl)phenyl]carbamate (8 g, 0.021 mol) in dichloromethane (80 ml) was added hydrazine hydrate (1.6 g, 0.032 mol) under stirring at room temperature. After stirring for 2 hours at room temperature, the resulting mixture was washed with 10% sodium bicarbonate solution (2x50 ml) and brine (50 ml). The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to provide 2.3 g of the titled product as oil, in 45% yield. This was used as such for the next reaction.
  • Step 6 Synthesis of (2S,5/f)-N-[(3-N-Boc-aminobenzyl)oxy]-6-(benzyloxy)-7-oxo-l,6- diazabicyclo [3.2.1] octane-2-carboxamide: To a stirred solution of sodium (25, 5 ?)-7-oxo-6- benzyloxy- l,6-diazabicyclo[3.2.1]octane-2-carboxylate (prepared according to the process disclosed in PCT/IB2013/059264) (2.87 g, 0.009 mol) in water (10 ml) were added successively EDC.HC1 (4.05 g, 0.021 mol) and HOBT (1.3 g, 0.009 mol) at room temperature.
  • tert- butyl ⁇ 3-[(aminooxy)methyl]phenyl ⁇ carbamate (2.3 g, 0.009 mol) was added to the above solution and stirred further for 5 hours.
  • the reaction mixture was extracted with ethyl acetate (2x10 ml).
  • the organic layer was dried over sodium sulfate and the solvent evaporated under reduced pressure to provide an oily residue.
  • This was purified by column chromatography over silica gel (60- 120 mesh size) by using mixture of acetone and hexane (20:80) as an eluent.
  • the combined solvent fractions were concentrated to provide 1.7 g of the titled product as white solid in 36% yield.
  • Step 7 Synthesis of (25,5/?)-A ⁇ -[(3-N-Boc-aminobenzyl)oxy]-6-(hydroxy)-7-oxo-l,6- diazabicyclo [3.2.1] octane-2-carboxamide: To a solution of a compound obtained in step 6 (1.7 g, 0.003 mmol) in a 1: 1 mixture of dichloro methane (8.5 ml) and dimethylformamide (8.5 ml) was added 10% palladium over carbon (425 mg, 50% wet) and was hydrogenated under atmosphere of hydrogen for 3 hours at room temperature under stirring. The resulting mixture was filtered through celite bed and washed with dichloromethane (10 ml). The filtrate was concentrated under reduced pressure to obtain 1.39 g of the titled product as oily mass in 100% yield.
  • Step 8 Synthesis of tetrabutylammonium salt of (2S,5/f)-A f -[(3-/V-Boc-aminobenzyl)oxy]-6-( sulfooxy)-7-oxo-l,6-diazabicyclo [3.2.1] octane-2-carboxamide: To a solution of a compound obtained in Step-7 (1.39 g, 03 mmol) pyridine (13 ml) was added pyridine sulphur trioxide complex (2.72 g, 17 mmol) at room temperature under argon atmosphere and stirring.
  • Step 9 Synthesis of (25,5 f)-N-[(3-aminobenzyl)oxy]-7-oxo-6-(sulfooxy)-l,6-diazabicyclo
  • Appropriate suspensions from the freshly grown cultures were prepared in normal saline so that about 10 4 CFU/spot of the organism was delivered on to the drug containing agar plates using automated multipoint inoculator (Mast, UK).
  • the plates were incubated in Biochemical oxygen demand (BOD) incubator at 37°C for 18 hours and then examined for growth.
  • BOD Biochemical oxygen demand

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), ou un stéréoisomère ou un sel pharmaceutiquement acceptable de ceux-ci, ainsi que leur préparation, des compositions pharmaceutiques les comprenant et leur utilisation dans le traitement et/ou la prévention d'infections bactériennes.
PCT/IB2017/053584 2016-06-17 2017-06-16 Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens WO2017216763A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621020847 2016-06-17
IN201621020847 2016-06-17

Publications (1)

Publication Number Publication Date
WO2017216763A1 true WO2017216763A1 (fr) 2017-12-21

Family

ID=59270065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053584 WO2017216763A1 (fr) 2016-06-17 2017-06-16 Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens

Country Status (1)

Country Link
WO (1) WO2017216763A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033560A1 (fr) * 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes
WO2014091268A1 (fr) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
EP2857401A1 (fr) * 2012-05-30 2015-04-08 Meiji Seika Pharma Co., Ltd. Nouvel inhibiteur de -lactamase et procédé de production de celui-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
EP2857401A1 (fr) * 2012-05-30 2015-04-08 Meiji Seika Pharma Co., Ltd. Nouvel inhibiteur de -lactamase et procédé de production de celui-ci
WO2014033560A1 (fr) * 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes
WO2014091268A1 (fr) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COATES ET AL., BR. J. PHARMACOL., vol. 152, no. 8, 2007, pages 1147 - 1154
GILMAN ET AL.: "Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th ed.", 1990, PERGAMON PRESS
GWYNN ET AL., ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1213, 2010, pages 5 - 19
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19

Similar Documents

Publication Publication Date Title
EP2748165B1 (fr) Dérivés 1,6-diazabicyclo[3,2,1]octane-7-one et leur utilisation dans le traitement d'infections bactériennes
CA2846107C (fr) Composes azotes et leur utilisation
CA2845108C (fr) Derives 1,6-diazabicyclo[3,2,1]octane-7-one et leur utilisation dans le traitent d'infections bacteriennes
EP3097105B1 (fr) Dérivés de 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane et leur utilisation comme agents antibactériens
WO2014033560A1 (fr) Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes
WO2016116788A1 (fr) Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
WO2016128867A1 (fr) Composés contenant de l'azétidinone et leur utilisation dans le traitement d'infections bactériennes
WO2017098425A1 (fr) Composés contenant du 7-oxo-6-(sulfo-oxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation dans le traitement d'infections bactériennes
WO2017037607A1 (fr) Dérivés de (2s,5r)-6-(sulfonyl)-7-oxo -1,6-diazabicyclo [3.2.1] octane-2-carboxamide substitués par (aminométhylidène)amino à activité antibactérienne
WO2017002086A1 (fr) Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
WO2017216764A1 (fr) Dérivés de n-(alcanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide et leur utilisation comme agents antibactériens
WO2017002087A1 (fr) Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
WO2017216763A1 (fr) Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens
WO2017002083A1 (fr) Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
WO2017060826A1 (fr) Composés d'acide acétique difluoro-(carbamoyl-1,6-diaza-bicyclo[3.2.1]oct-6-yloxy 2-substitué) et leur utilisation dans le traitement d'infections bactériennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17734832

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17734832

Country of ref document: EP

Kind code of ref document: A1